Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
McKinsey
Johnson and Johnson
US Army
McKesson
Healthtrust
Chinese Patent Office
US Department of Justice
Argus Health

Generated: July 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,192,571

« Back to Dashboard

Which drugs does patent 9,192,571 protect, and when does it expire?

Patent 9,192,571 protects ACUVAIL and is included in one NDA.

This patent has forty-four patent family members in twenty-two countries.
Summary for Patent: 9,192,571
Title:Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract: The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
Inventor(s): Farnes; Eldon Q. (Laguna Beach, CA), Attar; Mayssa (Placentia, CA), Schiffman; Rhett M. (Laguna Beach, CA), Chang; Chin-Ming (Tustin, CA), Graham; Richard S. (Irvine, CA), Welty; Devin F. (Foothill Ranch, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/552,057
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound;

Drugs Protected by US Patent 9,192,571

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan ACUVAIL ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 022427-001 Jul 22, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,192,571

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2009202969Jul 23, 2009

Non-Orange Book US Patents Family Members for Patent 9,192,571

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,842,714 Ketorolac tromethamine compositions for treating ocular pain ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,192,571

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 97734 ➤ Try a Free Trial
Russian Federation 2431469 ➤ Try a Free Trial
New Zealand 602445 ➤ Try a Free Trial
New Zealand 588367 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Fuji
Accenture
Deloitte
Baxter
Federal Trade Commission
Citi
Express Scripts
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.